Conduit Pharmaceuticals Inc
CDT3.230USD
-0.710-18.02%
종가 06/03, 16:00（ET）시세는 15분 지연됩니다
2.05M시가총액
손실P/E TTM
자세한 내용은 Conduit Pharmaceuticals Inc 회사
Conduit Pharmaceuticals, Inc. is a multi-asset clinical-stage, life science company. The Company facilitates the development and commercialization of clinical assets. The Company acquires and funds the development of Phase 2-ready assets, builds an integrated and advanced platform-driven approach powered by artificial intelligence (AI) and cybernetics, and seeks exit through third-party license deals following successful clinical trials. The Company’s asset pipeline includes AZD1656 (a Glucokinase Activator), AZD5658 (Glucokinase Activator), and AZD5904 (a Myeloperoxidase Inhibitor). AZD1656 is a glucokinase activator used in diabetes mellitus. It is used as a treatment option for Hashimoto’s Thyroiditis. AZD5904 includes a potent, irreversible inhibitor of human myeloperoxidase (MPO), for the treatment, prevention, and prophylaxis of idiopathic male infertility.
회사 정보
회사 코드CDT
회사 이름Conduit Pharmaceuticals Inc
상장일Feb 03, 2022
설립일2021
CEODr. Andrew Regan
직원 수6
유형Ordinary Share
회계 연도 종료Feb 03
주소4851 Tamiami Trail North
도시NAPLES
증권 거래소NASDAQ Capital Market Consolidated
국가United States of America
우편 번호34103
전화16464919132
웹사이트https://www.conduitpharma.com/
회사 코드CDT
상장일Feb 03, 2022
설립일2021
회사 임원
이름
이름/직위
직위
주식 보유
변동
Ms. Chele Chiavacci Farley
Ms. Chele Chiavacci Farley
Independent Director
Independent Director
2.37K
--
Mr. Simon Jeremy Fry
Mr. Simon Jeremy Fry
Director
Director
2.09K
--
Mr. James (Jamie) Bligh
Mr. James (Jamie) Bligh
Interim Chief Financial Officer, Senior Vice President - Strategy, Director
Interim Chief Financial Officer, Senior Vice President - Strategy, Director
25.00
--
Dr. Andrew Regan
Dr. Andrew Regan
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Freda Lewis-Hall, M.D.
Dr. Freda Lewis-Hall, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
이름
이름/직위
직위
주식 보유
변동
Ms. Chele Chiavacci Farley
Ms. Chele Chiavacci Farley
Independent Director
Independent Director
2.37K
--
Mr. Simon Jeremy Fry
Mr. Simon Jeremy Fry
Director
Director
2.09K
--
Mr. James (Jamie) Bligh
Mr. James (Jamie) Bligh
Interim Chief Financial Officer, Senior Vice President - Strategy, Director
Interim Chief Financial Officer, Senior Vice President - Strategy, Director
25.00
--
Dr. Andrew Regan
Dr. Andrew Regan
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Freda Lewis-Hall, M.D.
Dr. Freda Lewis-Hall, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
수익 분석
데이터 없음
데이터 없음
사업별
지역별
데이터 없음
주주
업데이트 시간: Wed, May 28
업데이트 시간: Wed, May 28
주주 통계
유형
주주 통계
주주
비율
Sarborg Ltd.
15.65%
Alliance Global Partners
9.10%
Corvus Capital, Ltd.
2.55%
Charles (Faith L.)
1.39%
AQR Capital Management, LLC
0.94%
Other
70.36%
주주 통계
주주
비율
Sarborg Ltd.
15.65%
Alliance Global Partners
9.10%
Corvus Capital, Ltd.
2.55%
Charles (Faith L.)
1.39%
AQR Capital Management, LLC
0.94%
Other
70.36%
유형
주주
비율
Corporation
19.25%
Research Firm
9.13%
Individual Investor
2.74%
Investment Advisor/Hedge Fund
2.24%
Investment Advisor
1.76%
Family Office
0.27%
Hedge Fund
0.03%
Other
64.58%
기관 주식 보유
업데이트 시간: Mon, Mar 3
업데이트 시간: Mon, Mar 3
보고 기간
기관 수
보유 주식
비율
변동
2025Q1
106
2.58M
25.94%
+1.87M
2024Q4
130
594.90K
17.01%
-86.94K
2024Q3
124
660.87K
58.37%
-5.97M
2024Q2
107
6.72M
81.00%
+6.04M
2024Q1
84
6.70M
79.51%
+6.03M
2023Q4
75
648.88K
85.40%
+35.12K
2023Q3
62
611.37K
80.63%
+498.71K
2023Q2
55
24.32K
82.28%
-88.18K
2023Q1
54
29.65K
100.40%
-91.89K
2022Q4
43
121.06K
86.60%
+3.67K
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
Corvus Capital, Ltd.
302.26K
3.17%
--
--
Dec 04, 2024
Charles (Faith L.)
50.05K
0.52%
+46.63K
+1.37K%
Mar 30, 2025
AstraZeneca PLC
95.05K
1%
+95.05K
--
Aug 07, 2024
Lewis-Hall (Freda C)
77.19K
0.81%
+47.61K
+160.94%
Mar 30, 2025
Murphy Canyon Acquisition Sponsor LLC
40.15K
0.42%
+32.61K
+432.53%
Sep 22, 2023
더 보기
관련 ETF
업데이트 시간: Tue, May 6
업데이트 시간: Tue, May 6
이름
비율
ProShares UltraPro Russell2000
0%
iShares Russell 2000 Growth ETF
0%
iShares Russell 2000 Value ETF
0%
Proshares Ultra Russell 2000
0%
iShares Micro-Cap ETF
0%
Global X Russell 2000 ETF
0%
ProShares Hedge Replication ETF
0%
ProShares UltraPro Russell2000
비율0%
iShares Russell 2000 Growth ETF
비율0%
iShares Russell 2000 Value ETF
비율0%
Proshares Ultra Russell 2000
비율0%
iShares Micro-Cap ETF
비율0%
Global X Russell 2000 ETF
비율0%
ProShares Hedge Replication ETF
비율0%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
유형
비율
Jan 23, 2025
Merger
100<1
Jan 23, 2025
Merger
100<1
Jan 23, 2025
Merger
100<1
Jan 23, 2025
Merger
100<1
날짜
유형
비율
Jan 23, 2025
Merger
100<1
Jan 23, 2025
Merger
100<1
Jan 23, 2025
Merger
100<1
Jan 23, 2025
Merger
100<1
